Narang Anil, Bose Anuradha, Pandit Anand Nilkanth, Dutta Phalguni, Kang Gagandeep, Bhattacharya Sujit Kumar, Datta Sanjoy Kumar, Suryakiran P V, Delem Andrée, Han Htay Htay, Bock Hans Ludwig
Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
Hum Vaccin. 2009 Jun;5(6):414-9. doi: 10.4161/hv.5.6.8176. Epub 2009 Jun 15.
This study was undertaken to assess the immunogenicity, reactogenicity and safety of two doses of an oral live-attenuated human rotavirus vaccine, strain RIX4414 (Rotarix()) in an Indian setting.
The seroconversion rate observed one month post-dose 2 in the RIX4414 group 58.3% [95% CI: 48.7; 67.4] was significantly higher when compared to the placebo group 6.3%; [95% CI: 2.5; 12.5]. The reactogenicity and safety profile was similar for both groups.
Healthy infants (N = 363), approximately eight weeks of age were enrolled to receive two doses of RIX4414 vaccine (n = 182) or placebo (n = 181) separated by one month. To assess the immune response, blood samples were taken before vaccination and one month post-dose 2 of RIX4414/placebo. Solicited symptoms were collected for eight-days post each dose and safety data was collected throughout the study.
Two doses of RIX4414 (Rotarix()) were immunogenic, had a good safety profile and were well-tolerated when administered to healthy Indian infants.
ClinicalTrials.gov; NCT00289172; eTrack 103792.
本研究旨在评估两剂口服减毒活人类轮状病毒疫苗RIX4414(Rotarix())在印度环境中的免疫原性、反应原性和安全性。
RIX4414组在第2剂接种后1个月观察到的血清转化率为58.3%[95%置信区间:48.7;67.4],与安慰剂组的6.3%[95%置信区间:2.5;12.5]相比显著更高。两组的反应原性和安全性概况相似。
纳入年龄约8周的健康婴儿(N = 363),接受两剂RIX4414疫苗(n = 182)或安慰剂(n = 181),间隔1个月。为评估免疫反应,在接种疫苗前以及接种RIX4414/安慰剂第2剂后1个月采集血样。在每次接种后8天收集主动报告的症状,并在整个研究过程中收集安全性数据。
两剂RIX4414(Rotarix())具有免疫原性,安全性良好,在健康的印度婴儿中给药时耐受性良好。
ClinicalTrials.gov;NCT00289172;电子追踪号103792。